What Innovatus Capital Partners does

Innovatus Capital Partners, LLC is a private investment adviser and portfolio management firm founded in September 2016 by David Schiff (CEO) and Andrew Dym (President), both former senior members of Perella Weinberg Partners' Asset Based Value Strategy. The firm launched with approximately $1.9 billion in assets under management and operates two principal business divisions: Innovatus Life Sciences, which provides $20 million to $150 million+ in senior secured debt and equity financing to late-stage development and commercial-stage biotechnology, pharmaceutical, medical device, diagnostic, and life sciences tools companies; and Innovatus Real Estate, which acquires, owns, and enhances core and core-plus Class A office properties across top-50 U.S. metropolitan areas. The real estate portfolio currently comprises 15 assets totaling approximately 3.8 million square feet across the Mid-Atlantic, Southeast, Southwest, Western, and Northeast United States. Innovatus also operates a smaller Latin American Trade Finance platform for agricultural commodity transactions in Brazil and Paraguay.

The firm generates revenue through a combination of management and advisory fees on committed fund capital, interest income on senior secured debt instruments (typically structured with milestone-based interest-only periods, warrant coverage, and up to 20% equity conversion features), carried interest on investment returns above preferred return thresholds, and rental income from the directly-owned real estate portfolio. Capital is raised from institutional investors, family offices, and high-net-worth individuals, with the founders' networks and a strategic advisory board (including Israel 'Izzy' Englander of Millennium Management as advisor and Bart Winokur as Advisory Board Chairman) providing credibility and deal flow. Property management and leasing are executed through a national partnership with Lincoln Property Company. The Life Sciences division has committed approximately $1.5 billion in senior secured debt across 33+ portfolio companies to date, supported by an investment team with over 200 combined years of healthcare investing experience and an advisory board including Geoffrey Duyk (ex-TPG Biotechnology), Dr. Luis Diaz (Memorial Sloan Kettering), and Dr. Darryl Elmouchi (Providence COO). The firm is headquartered at 777 Third Avenue, 25th Floor, New York, NY.

Name

Innovatus Capital Partners

Legal name

Innovatus Capital Partners, LLC

Website

http://www.innovatuscp.com/

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Innovatus Capital Partners is a private investment adviser founded in 2016 that provides senior secured debt and equity financing to life sciences companies and owns a 3.8M-square-foot Class A office real estate portfolio, serving institutional investors, family offices, and high-net-worth individuals.

Ownership category

akta.pro rank

Product category

Alternative Asset Management

NAICS

Portfolio Management and Investment Advice (523940), All Other Financial Investment Activities (52399)

SIC

Investment Advice (6282), Investors, Nec (6799), Real Estate Dealers (For Their Own Account) (6532)

akta.pro primary industry

Direct Lending — Venture Debt (FSAHAJAD)

akta.pro secondary industries

Real Estate Credit / Debt Funds (FSANAEAJ), Real Estate Funds — Opportunistic / Development (FSANAEAI)

Keywords

• Private debt financing
• Life sciences lending
• Commercial real estate investment
• Alternative asset management
• Special situations investing

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Others

Revenue model

1. Management and Advisory Fees: Innovatus charges management fees and advisory fees to funds and investment vehicles, consistent with standard private equity/credit fund economics. Capital is raised from institutional investors, family offices, and high-net-worth individuals into vehicles including Innovatus Structured Credit Real Estate Fund I.
2. Interest Income on Debt Investments: The firm generates interest income through direct lending and senior secured debt instruments provided to portfolio companies across life sciences and other sectors. Terms include interest-only periods tied to milestones and conversion features (e.g., up to 20% conversion into equity).
3. Performance / Carried Interest: As a private equity-style investment firm with long-term lockup requirements, Innovatus earns carried interest on investment returns above preferred thresholds, aligning GP and LP incentives.
4. Real Estate Rental Income: The firm acquires, owns, and enhances Class A office properties generating rental income from tenants. The portfolio totals approximately 3.8 million square feet across 15 assets in the Mid-Atlantic, Southeast, Southwest, and Western U.S.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

Innovatus Capital Partners is an independent investment adviser that deploys private capital across three primary strategies: senior secured debt and equity financing for late-stage life sciences companies ($20M–$150M+ per transaction), acquisition and management of Class A office properties in top 50 U.S. metropolitan areas (approximately 3.8 million square feet across 15 assets), and Latin American trade finance. The firm manages capital through dedicated vehicles such as the Innovatus Structured Credit Real Estate Fund I, raising funds from institutional investors, family offices, and high-net-worth individuals.

Product overview

Innovatus Capital Partners is an independent investment adviser and portfolio management firm that operates multiple investment strategies. The firm provides private capital solutions across three primary areas: (1) Life Sciences investments through senior secured debt and equity financing to biotechnology, pharmaceutical, medical device, diagnostic, and life sciences tools companies; (2) Real Estate investments acquiring and managing core and core-plus office properties across U.S. metropolitan areas; and (3) Latin American Trade Finance providing commodity and trade financing solutions. The firm manages capital through dedicated funds including the Innovatus Structured Credit Real Estate Fund I and maintains a portfolio of approximately 33 life sciences portfolio companies spanning active investments and exited positions.

Differentiator

Problem solved

Functional benefit

Products and services

• Innovatus Life Sciences Provides $20M–$150M+ in senior secured debt and equity investments to public and private late-stage development and commercial-stage life sciences companies needing growth capital, with creative structuring including milestone-based interest-only periods and equity conversion features.
• Innovatus Real Estate Acquires, owns, and enhances a diversified portfolio of high-quality core and core-plus Class A office properties in top 50 U.S. metros, totaling approximately 3.8 million square feet across 15 assets in the Mid-Atlantic, Southeast, Southwest, and Western U.S.
• Latin American Trade Finance Provides commodity and trade finance structures to agricultural exporters and farm supply distributors in Latin American markets such as Brazil and Paraguay.
• Innovatus Structured Credit Real Estate Fund I Investment vehicle focused on suburban office properties and real estate debt and equity transactions, structured as a private fund for institutional, family office, and high-net-worth investors.

Quantifiable outcome

• $1.5 billion in senior secured debt commitments to leading life sciences companies
• +3 more outcomes

Named customers15 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Eight partnerships are on record, tiered major and core.

• Pfizer Inc.majorStrategic or Co-development Partner · 9 April 2021Innovatus's portfolio company Celcuity licensed the pan-PI3K/mTOR inhibitor gedatolisib from Pfizer, with Pfizer eligible for up to $330M in development and sales milestones plus royalties. Innovatus simultaneously provided $25M debt financing to Celcuity to support development.
• Lincoln Property CompanycoreChannel Partner/ Reseller/ DistributorLincoln Property Company serves as Innovatus's national property management and leasing partner across the entire 15-asset, 3.8M SF real estate portfolio. LPC also assists in sourcing and evaluating acquisition opportunities across U.S. markets.
• LPC WestcoreChannel Partner/ Reseller/ DistributorLPC West manages multiple Innovatus real estate assets including the Overlake 520 Campus in Bellevue, WA, and other properties, providing property management and leasing services.
• Geoffrey Duyk (Advisory Board)coreOthersFormer Head of TPG Biotechnology/Healthcare; President of R&D at Exelixis; Founding Scientific Staff at Millennium Pharmaceuticals. Provides scientific, technical, and commercial expertise to the Life Sciences investment team.
• Luis Diaz, M.D. (Advisory Board)coreOthersHead of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center. Renowned for pioneering work on circulating tumor DNA diagnostics and immune checkpoint blockade for mismatch repair deficient tumors.
• Darryl Elmouchi, M.D. (Advisory Board)coreOthersChief Operating Officer of Providence health system, providing healthcare operations and clinical expertise to support life sciences investment decisions and portfolio company guidance.
• Israel 'Izzy' EnglandercoreOthersFounder, Chairman and CEO of Millennium Management ($34B AUM hedge fund) joined Innovatus's advisory board at formation in September 2016 as strategic advisor. His involvement provides significant credibility and network access.
• Bart WinokurcoreOthersFormer Chairman and CEO of Dechert LLP (1996–2011), joined as Chairman of Innovatus Advisory Board in February 2017. Brings 40+ years of M&A and legal expertise from one of the largest law firms.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Hercules Capital: Public specialty finance company (NYSE: HTGC) and the dominant independent venture debt provider to life sciences companies. Direct competitor in biotech, medtech, and diagnostics senior secured lending in the same $20M-$150M+ check-size range that Innovatus Life Sciences targets.
• Trinity Capital: Public specialty finance company (NASDAQ: TRIN) providing venture debt and equipment financing across life sciences, tech, and clean energy. Overlaps directly with Innovatus Life Sciences on biotech/medtech term loans.
• Runway Growth Finance: Public BDC (NASDAQ: RWAY) providing senior-secured term loans to venture and growth-stage life sciences and technology companies. Closely overlapping check size, structure, and target issuer profile with Innovatus Life Sciences.
• Horizon Technology Finance: Public BDC (NASDAQ: HRZN) providing secured debt to life sciences and technology companies from venture-backed to publicly listed stages. Closest direct comparable to Innovatus Life Sciences in deal structure, pricing, and target-company profile.
• Pearlmark Real Estate Partners: Boutique private real estate investment manager focused on commercial equity and debt across property types and U.S. geographies. Closest boutique peer to Innovatus Real Estate on suburban office/core-plus strategy and fund economics.

Broad incumbents

• Angelo, Gordon & Co. Multi-strategy alternative investment manager (now part of TPG) historically focused on real estate, credit, and special situations. Highly comparable investment philosophy and platform structure to Innovatus, but at meaningfully larger scale.
• White Oak Global Advisors: Large private credit and direct lending platform with multi-billion AUM. Comparable as an alternative asset manager providing senior secured loans to upper-middle-market and structured credit borrowers, though broader in sector focus than Innovatus.
• Perella Weinberg Partners: The advisory and asset management firm that spawned Innovatus — David Schiff and Andrew Dym led the Asset Based Value Strategy at Perella Weinberg before spinning it out in 2016. Same founding DNA in special-situations, structured credit, and asset-based investing.
• CIM Group: Multi-strategy alternative asset manager with substantial real estate and credit platforms. Broader and larger than Innovatus, but operates a similar dual-platform model combining commercial real estate acquisitions with private credit and special situations investing.

Emerging players

• K2 HealthVentures: Private life sciences-focused alternative asset manager providing debt and equity to healthcare and biotech companies. Smaller and earlier-stage than Innovatus's life sciences platform but competes for similar borrowers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments27 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Innovatus Capital Partners